1,2-Benzodiazepine
- Generic Name
- 1,2-Benzodiazepine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H8N2
- CAS Number
- 264-60-8
- Unique Ingredient Identifier
- M0Q7802G2B
- Background
Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Mindfulness Program Shows 67% Reduction in Opioid Cravings in Clinical Trial
• A 24-week clinical trial demonstrated that the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) program reduced opioid cravings by 67% compared to 44% in standard recovery support.
• The study, published in JAMA Network Open, found significant anxiety reduction in both treatment groups, though the mindfulness intervention did not show superior effects on actual opioid use.
• Researchers suggest mindfulness practices may work by enhancing interoceptive awareness and improving emotion regulation, with potential for implementation in both in-person and online settings.
Aquestive Therapeutics Advances Anaphylm NDA Submission and Alopecia Areata Trial
• Aquestive Therapeutics is on track to submit its NDA for Anaphylm sublingual film in Q1 2025, aiming to provide the first orally delivered epinephrine for severe allergic reactions.
• The company is actively recruiting for the Anaphylm pediatric clinical trial, expanding access to this potential treatment across different age groups.
• Aquestive's AQST-108 topical gel completed a pre-IND meeting with the FDA and is set to begin a Phase 2a trial for alopecia areata in Q2 2025.
Apitegromab Shows Promise in Phase III Spinal Muscular Atrophy Trial, Scholar Rock Reports
• Scholar Rock's investigational drug apitegromab has achieved its primary endpoint of motor function improvement in a Phase III clinical trial for spinal muscular atrophy patients.
• New research demonstrates potential breakthrough in PML treatment using directly isolated allogeneic virus-specific T cells, showing improved mortality rates and functional outcomes.
• A novel masked tapering approach combined with behavioral intervention has successfully helped older adults with insomnia discontinue benzodiazepine receptor agonists.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath